Our ORR prediction may be further improved by including new lesion formation in the model, since a large portion of the patients with low PD-L1 expression in Study 1108, despite having a > 30% tumor size reduction, was categorized as non-responder due to detection of new lesion(s)24. The gene discussed is CD274; the disease is neoplasm.